Syndax Pharmaceuticals SNDX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's financing cash flow?
- Syndax Pharmaceuticals (SNDX) reported financing cash flow of $7.92M in Q1 2026.
- How has Syndax Pharmaceuticals's financing cash flow changed year-over-year?
- Syndax Pharmaceuticals's financing cash flow increased by 751.4% year-over-year, from $930K to $7.92M.
- What is the long-term trend for Syndax Pharmaceuticals's financing cash flow?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's financing cash flow has grown at a -41.7% compound annual growth rate (CAGR), from $118.46M to $13.68M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.